Melanotan 1 (Afamelanotide): MC1R Agonist Tanning Peptide Research Guide

Key Points

• Melanotan 1 (afamelanotide) is a synthetic linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH)
• Highly selective for melanocortin-1 receptor (MC1R), distinguishing it from the non-selective Melanotan 2
• FDA approved as Scenesse (afamelanotide implant) in October 2019 for erythropoietic protoporphyria (EPP)
• Also approved by EMA (2014) and TGA (Australia) for EPP treatment
• Primary mechanism involves eumelanin production for photoprotection without UV exposure requirement
• Research demonstrates significantly improved safety profile compared to Melanotan 2 due to MC1R selectivity

Table of Contents

1. Introduction
2. Molecular Structure
3. Mechanism of Action
4. FDA-Approved Scenesse for EPP
5. Photoprotection Research
6. Comparison to Melanotan 2
7. Safety Profile
8. Research Applications
9. Frequently Asked Questions
10. Conclusion
11. References

Introduction

Melanotan 1, known by its International Nonproprietary Name (INN) as afamelanotide, represents a landmark achievement in melanocortin peptide pharmacology. This synthetic linear tridecapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) was developed at the University of Arizona in the 1980s as part of research into photoprotective compounds that could stimulate melanogenesis without requiring ultraviolet radiation exposure.

Unlike its cyclic counterpart Melanotan 2, which activates multiple melanocortin receptor subtypes and was abandoned due to safety concerns, Melanotan 1 demonstrates high selectivity for the melanocortin-1 receptor (MC1R). This selectivity translates to a focused mechanism of action centered on melanocyte stimulation without the cardiovascular, sexual, and appetite-modulating effects associated with MC3R and MC4R activation.

The clinical development of afamelanotide culminated in regulatory approvals for treating erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by extreme photosensitivity. The European Medicines Agency (EMA) granted conditional approval in 2014, followed by FDA approval in October 2019 under the brand name Scenesse. These approvals validated the compound's photoprotective mechanism and established the first melanocortin-based therapy for a dermatological condition.

This article provides a comprehensive scientific overview of Melanotan 1, examining its molecular structure, MC1R-mediated mechanism, regulatory-approved applications, photoprotection research, and comparative analysis with Melanotan 2. Understanding these aspects is essential for researchers investigating melanocortin biology and clinicians treating photosensitivity disorders.

Important Distinction: This article addresses both the regulatory-approved pharmaceutical product (Scenesse/afamelanotide implant) and research-grade Melanotan 1. While chemically related, these exist in different contexts. Scenesse is a prescription medication approved for EPP, while research Melanotan 1 refers to the compound used in laboratory investigations.

Molecular Structure

Chemical Properties

Structural Characteristics

Melanotan 1 is a linear tridecapeptide that closely mirrors the structure of endogenous alpha-MSH while incorporating strategic modifications to enhance metabolic stability and receptor binding:

1. Norleucine Substitution: The methionine residue at position 4 is replaced with norleucine (Nle), preventing oxidative degradation that would otherwise limit the peptide's stability and shelf life.

2. D-Phenylalanine Incorporation: Position 7 contains D-phenylalanine rather than the natural L-isomer, conferring resistance to proteolytic enzymes and enhancing receptor binding affinity.

3. Acetylated N-terminus: The N-terminal serine carries an acetyl cap, providing protection against aminopeptidase-mediated degradation.

4. Amidated C-terminus: The C-terminal valine is amidated, protecting against carboxypeptidase activity.

5. Linear Architecture: Unlike cyclic Melanotan 2, afamelanotide maintains a linear structure, contributing to its different receptor selectivity profile.

Comparison to Native Alpha-MSH

Alpha-MSH is a tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) derived from post-translational processing of proopiomelanocortin (POMC). Afamelanotide differs from native alpha-MSH at two positions:

• Position 4: Norleucine replaces methionine
• Position 7: D-phenylalanine replaces L-phenylalanine

These modifications result in approximately 10-fold greater potency than native alpha-MSH and significantly extended biological half-life, enabling therapeutic applications not possible with the endogenous peptide.

Mechanism of Action

MC1R Selectivity

The defining pharmacological characteristic of Melanotan 1 is its high selectivity for the melanocortin-1 receptor (MC1R). This selectivity distinguishes it from Melanotan 2 and explains its more favorable safety profile:

Melanogenesis Pathway

MC1R activation by Melanotan 1 initiates a well-characterized signaling cascade leading to melanin production:

1. Receptor Binding: Afamelanotide binds to MC1R on epidermal melanocytes with high affinity and selectivity.

2. G-Protein Activation: MC1R is a G protein-coupled receptor (GPCR) that couples primarily to Gs proteins upon ligand binding.

3. Adenylyl Cyclase Stimulation: Gs activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) concentrations.

4. PKA Activation: Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets.

5. CREB Phosphorylation: PKA-mediated phosphorylation of CREB (cAMP response element-binding protein) at Ser133 activates this transcription factor.

6. MITF Upregulation: CREB activation increases expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte differentiation and function.

7. Melanogenic Enzyme Expression: MITF upregulates expression of tyrosinase, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2/DCT), the key enzymes in melanin biosynthesis.

8. Eumelanin Production: The net effect is increased synthesis of eumelanin (brown-black pigment) within melanosomes, preferentially over pheomelanin (red-yellow pigment).

9. Pigment Distribution: Melanin-containing melanosomes are transferred to surrounding keratinocytes through dendritic processes, distributing photoprotective pigment throughout the epidermis.

Photoprotective Mechanisms

The increased eumelanin production induced by Melanotan 1 provides photoprotection through multiple mechanisms:

UV Absorption: Eumelanin efficiently absorbs UV radiation across the UVA and UVB spectrum, preventing penetration to DNA-containing cellular structures.

Free Radical Scavenging: Eumelanin acts as an antioxidant, neutralizing reactive oxygen species generated by UV exposure.

DNA Protection: By absorbing UV energy, melanin shields nuclear and mitochondrial DNA from photodamage that could lead to mutations.

Reduced Sunburn Response: Enhanced basal pigmentation decreases the threshold for sunburn (minimal erythemal dose), though complete UV avoidance remains necessary for conditions like EPP.

FDA-Approved Scenesse for EPP

Erythropoietic Protoporphyria Overview

Erythropoietic protoporphyria (EPP) is a rare inherited metabolic disorder caused by deficiency of ferrochelatase, the final enzyme in heme biosynthesis. This deficiency leads to accumulation of protoporphyrin IX in erythrocytes, plasma, and skin:

• Prevalence: Approximately 1 in 75,000 to 1 in 200,000 individuals
• Inheritance: Typically autosomal dominant with variable penetrance
• Pathophysiology: Protoporphyrin IX absorbs visible light (particularly 400-410 nm), generating reactive oxygen species that cause severe cutaneous photosensitivity
• Symptoms: Burning pain, swelling, and erythema upon sun exposure, often within minutes
• Impact: Profound quality-of-life limitations due to light avoidance requirements

Clinical Development

The clinical development of afamelanotide for EPP followed a rigorous pathway:

Phase II Studies:

• Demonstrated increased pain-free time in sunlight for EPP patients
• Established implant formulation and dosing schedule
• Characterized safety profile in target population

Phase III Pivotal Trials (CUV039 and CUV029):

• Randomized, double-blind, placebo-controlled studies
• Primary endpoint: Time to first phototoxic reaction under standardized light exposure
• Secondary endpoints: Quality of life measures, total sun exposure time
• Results showed significantly increased time to first phototoxic reaction versus placebo

Regulatory Approvals

European Medicines Agency (EMA) - December 2014:

• Conditional marketing authorization for Scenesse
• Indication: Prevention of phototoxicity in adult patients with EPP
• Administered as subcutaneous implant (16 mg afamelanotide)
• Dosing: Every 2 months before and during sun exposure periods

U.S. Food and Drug Administration (FDA) - October 2019:

• Approved under orphan drug designation
• Indication: To increase pain-free light exposure in adult patients with a history of phototoxic reactions from EPP
• Same formulation as European approval
• Notable as first FDA-approved treatment specifically for EPP

Therapeutic Goods Administration (Australia):

• Approved for EPP treatment
• Similar indication and dosing to EU approval

Treatment Protocol

The approved Scenesse treatment involves:

• Formulation: Bioresorbable subcutaneous implant containing 16 mg afamelanotide
• Administration: Implanted in the suprascapular area by healthcare professionals
• Dosing Schedule: Every 60 days (2 months)
• Treatment Period: Before and during periods of expected sun exposure
• Maximum Annual Use: Typically 4-6 implants per year based on seasonal sun exposure

Photoprotection Research

Preclinical Photoprotection Studies

Extensive preclinical research has characterized Melanotan 1's photoprotective properties:

Rodent Models:

• Demonstrated melanogenesis induction in mouse models without UV exposure
• Showed dose-dependent increases in epidermal melanin content
• Documented protection against UV-induced erythema and DNA damage
• Established pharmacokinetic parameters guiding clinical development

Cell Culture Studies:

• Confirmed MC1R-dependent activation of melanogenic pathways
• Demonstrated preferential eumelanin over pheomelanin synthesis
• Characterized signaling cascade from receptor to melanogenic enzymes
• Showed protective effects against UV-induced oxidative stress

Human Photoprotection Studies

Clinical studies have evaluated photoprotective effects in various populations:

Healthy Volunteer Studies:

• Increased melanin density measured by spectrophotometry and biopsy
• Reduced minimal erythemal dose (MED) indicating enhanced UV tolerance
• Pigmentation onset within 2-3 weeks of treatment initiation
• Effects persisted for weeks after treatment discontinuation

Fair-Skinned Populations:

• Significant increases in constitutive pigmentation in Fitzpatrick skin types I-II
• Enhanced tanning response to subsequent UV exposure
• Potential reduction in sunburn susceptibility

Photosensitivity Disorders:

• EPP trials demonstrating increased pain-free light exposure
• Ongoing research in other porphyrias
• Investigation in polymorphous light eruption and other photodermatoses

Comparative Photoprotection Efficacy

Research comparing melanocortin agonists for photoprotection has shown:

Comparison to Melanotan 2

Structural Differences

Understanding the structural distinctions between Melanotan 1 and Melanotan 2 explains their differing pharmacological profiles:

Pharmacological Differences

The distinct structures produce markedly different pharmacological profiles:

Receptor Activity:

• Melanotan 1: Primarily activates MC1R with minimal activity at other melanocortin receptors
• Melanotan 2: Activates MC1R, MC3R, MC4R, and MC5R with significant potency

Central Nervous System Effects:

• Melanotan 1: Limited CNS effects due to minimal MC3R/MC4R activity
• Melanotan 2: Significant CNS effects including appetite suppression and sexual arousal through MC4R

Cardiovascular Effects:

• Melanotan 1: Minimal cardiovascular activity
• Melanotan 2: Documented hypertension and tachycardia through MC3R/MC4R

Sexual Function:

• Melanotan 1: No documented sexual effects
• Melanotan 2: Pro-erectile and libido-enhancing effects (basis for PT-141 development)

Clinical Development Trajectories

The two compounds followed dramatically different development paths:

Melanotan 1 (Afamelanotide):

• Systematic clinical development through Phase I-III trials
• Regulatory review and approval by EMA, FDA, and TGA
• Approved indication for EPP
• Manufactured under GMP conditions as Scenesse
• Ongoing research for additional indications

Melanotan 2:

• Early clinical development abandoned due to safety concerns
• No regulatory approval by any major agency
• Classified as unapproved drug with regulatory warnings
• Available only through unregulated markets
• Associated with multiple adverse event reports including melanoma cases

Related compound PT-141 (Bremelanotide): Originally derived from Melanotan 2 research, PT-141 was developed for sexual function and achieved FDA approval as Vyleesi in 2019, demonstrating that selective melanocortin receptor targeting can lead to successful drug development.

Safety Comparison

The selectivity difference translates to substantial safety distinctions:

Safety Profile

Clinical Trial Safety Data

Safety data from afamelanotide clinical trials characterize a generally well-tolerated compound:

Common Adverse Events (EPP Trials):

Pigmentation Changes:

• Expected darkening of skin, freckling, and moles
• Changes typically reversible upon discontinuation
• Dermatological monitoring recommended during treatment
• No atypical nevus changes or melanoma signals in controlled trials

Long-term Safety Observations

Post-marketing surveillance and long-term extension studies have provided additional safety information:

• No melanoma cases attributed to afamelanotide in clinical development
• Pigmentation changes remain reversible
• No unexpected adverse events emerged with extended use
• Regular dermatological examinations recommended per labeling

Contraindications and Precautions

Product labeling identifies the following considerations:

Contraindications:

• Known hypersensitivity to afamelanotide or excipients
• Concurrent use not studied with other melanocortin agonists

Precautions:

• Skin examinations recommended at initiation and periodically during treatment
• May darken pre-existing nevi requiring monitoring
• Effect on skin neoplasms not fully characterized
• Limited data in hepatic or renal impairment

Comparison to Melanotan 2 Safety Concerns

The contrast with Melanotan 2's documented safety issues is substantial:

Issues Documented with Melanotan 2 (Not Observed with Melanotan 1):

• Melanoma case reports in users
• Atypical nevus changes
• Cardiovascular symptoms (hypertension, tachycardia)
• Sexual side effects including priapism
• Significant nausea and flushing
• Contamination concerns from unregulated manufacturing

Research Applications

Dermatological Research

Melanotan 1 serves as an important research tool in dermatology:

Melanogenesis Studies:

• Investigation of MC1R signaling pathways
• Characterization of melanocyte biology
• Development of photoprotective strategies
• Understanding pigmentation disorders

Photodermatology:

• Research into photosensitivity disorder mechanisms
• Development of treatments for conditions beyond EPP
• Investigation of UV damage prevention strategies
• Studies of vitamin D synthesis in enhanced pigmentation states

Melanocortin System Research

As a selective MC1R agonist, Melanotan 1 enables targeted investigation:

• Structure-activity relationship studies
• MC1R pharmacology characterization
• Comparison with less selective melanocortin agonists
• Investigation of MC1R variants (polymorphisms associated with fair skin, red hair)

Ongoing Clinical Research

Clinical research continues to explore additional applications:

Vitiligo:

• Investigation of repigmentation potential
• Combination with phototherapy approaches
• Studies in segmental and non-segmental vitiligo

Polymorphous Light Eruption:

• Evaluation as prophylactic treatment
• Comparison to traditional phototherapy protocols

Other Porphyrias:

• Research in variegate porphyria and other photosensitive porphyrias
• Potential expansion of approved indications

Skin Cancer Prevention:

• Theoretical investigation of enhanced melanization for UV protection
• Long-term studies examining photocarcinogenesis rates

Frequently Asked Questions

What is the difference between Melanotan 1 and Melanotan 2?

Melanotan 1 (afamelanotide) is a linear 13-amino acid peptide that selectively activates MC1R, while Melanotan 2 is a cyclic 7-amino acid peptide that non-selectively activates multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R). This selectivity difference results in Melanotan 1 having a significantly better safety profile, leading to regulatory approval for EPP, while Melanotan 2 has not been approved by any regulatory agency due to safety concerns including documented cardiovascular effects and potential melanoma associations.

Is Melanotan 1 FDA approved?

Yes, Melanotan 1 (as afamelanotide, brand name Scenesse) was approved by the FDA in October 2019 for increasing pain-free light exposure in adult patients with erythropoietic protoporphyria (EPP). It was previously approved by the European Medicines Agency in 2014 and by Australia's TGA. Scenesse is administered as a subcutaneous implant by healthcare professionals.

How does Melanotan 1 provide photoprotection?

Melanotan 1 activates MC1R receptors on melanocytes, triggering a signaling cascade that upregulates melanogenic enzymes and increases eumelanin production. Eumelanin provides photoprotection by absorbing UV radiation, scavenging free radicals, and shielding DNA from photodamage. This occurs without requiring UV exposure, which is particularly valuable for patients with extreme photosensitivity conditions like EPP.

What are the main side effects of Melanotan 1?

In clinical trials, the most common side effects of afamelanotide were headache (20%), nausea (17%), nasopharyngitis (15%), implant site reactions (10%), and fatigue (8%). Expected pigmentation changes including skin darkening and freckling were observed but are generally reversible upon discontinuation. Unlike Melanotan 2, no cardiovascular or sexual side effects have been documented with Melanotan 1.

Can Melanotan 1 cause melanoma?

Clinical trials of afamelanotide have not shown any melanoma signal, and no melanoma cases have been attributed to the drug in controlled studies. However, because the compound increases melanocyte activity, dermatological monitoring is recommended during treatment. This contrasts with Melanotan 2, where case reports have documented melanoma in users, though causality has not been definitively established.

How is Scenesse administered?

Scenesse is a 16 mg afamelanotide implant administered subcutaneously in the suprascapular area (above the hip) by a healthcare professional. The implant is bioresorbable and does not require removal. Treatment is typically given every 60 days (2 months) before and during periods of expected sun exposure, with patients receiving approximately 4-6 implants per year.

Is Melanotan 1 used for tanning?

While Melanotan 1 does increase skin pigmentation through melanogenesis, it is not approved for cosmetic tanning purposes. The FDA-approved indication is specifically for erythropoietic protoporphyria, a serious medical condition. Research-grade Melanotan 1 is intended for laboratory investigation, not human use outside of approved medical contexts.

Conclusion

Melanotan 1 (afamelanotide) represents a successful translation of melanocortin research into an approved therapeutic agent. Its high selectivity for MC1R, combined with strategic structural modifications that enhance stability and potency, produces a compound with demonstrated efficacy in stimulating photoprotective eumelanin synthesis while avoiding the concerning off-target effects associated with non-selective melanocortin agonists.

The regulatory approval of Scenesse for erythropoietic protoporphyria marks a significant milestone for patients with this debilitating photosensitivity disorder and validates decades of research into melanocortin biology. The compound's ability to increase pain-free light exposure in EPP patients addresses an unmet medical need where few therapeutic options previously existed.

The contrast with Melanotan 2 is instructive for peptide pharmacology. While both compounds originated from similar research programs at the University of Arizona, their divergent receptor selectivity profiles led to dramatically different fates. Melanotan 1's MC1R selectivity produced a compound suitable for regulatory approval, while Melanotan 2's non-selective activation of MC3R and MC4R generated concerning cardiovascular and other effects that prevented its clinical development.

For researchers, Melanotan 1 serves as both an approved pharmaceutical and a valuable tool for investigating MC1R biology, melanogenesis pathways, and photoprotection mechanisms. Ongoing clinical research may expand its approved indications to include other photosensitivity disorders, potentially offering relief to additional patient populations.

The distinction between the approved pharmaceutical product (Scenesse) and research-grade Melanotan 1 remains important. Scenesse represents a quality-controlled, regulated medication with established safety and efficacy data, while research materials exist outside regulatory frameworks and should be used only for legitimate scientific investigation.

Melanotan 1 exemplifies how targeted receptor selectivity can transform a research compound into an approved therapy, providing a template for future melanocortin-targeted drug development while underscoring the importance of selectivity in peptide pharmacology.

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. doi:10.1056/NEJMoa1411481

3. Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. doi:10.1111/bjd.13598

4. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869-1878. doi:10.1038/sj.jid.5700317

5. Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004;140(7):827-835. doi:10.1001/archderm.140.7.827

6. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815-823. doi:10.1007/s40262-016-0501-5

7. Harms JH, Lautenschlager S, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med. 2009;360(3):306-307. doi:10.1056/NEJMc0805682

8. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754

9. Garcia-Borron JC, Sanchez-Laorden BL, Jimenez-Cervantes C. Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res. 2005;18(6):393-410. doi:10.1111/j.1600-0749.2005.00278.x

10. Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie drugs' and 'sun tan jabs'? Br J Dermatol. 2010;163(3):451-455. doi:10.1111/j.1365-2133.2010.09891.x

11. U.S. Food and Drug Administration. FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder. FDA News Release. October 8, 2019.

12. European Medicines Agency. Scenesse: EPAR - Product Information. EMA/H/C/002548. Updated 2023.

13. Clinuvel Pharmaceuticals. Scenesse (afamelanotide) prescribing information. 2019.

14. Abdel-Malek ZA, Kadekaro AL, Swope VB. Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res. 2010;23(2):171-186. doi:10.1111/j.1755-148X.2010.00679.x

15. Hruby VJ, Wilkes BC, Hadley ME, et al. alpha-Melanotropin: the minimum active sequence in the frog skin bioassay. J Med Chem. 1987;30(11):2126-2130. doi:10.1021/jm00394a033

16. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. ScientificWorldJournal. 2010;10:1840-1853. doi:10.1100/tsw.2010.173

17. Bohm M, Luger TA. Melanocortins in fibroblast biology: current update and future perspective for dermatology. Exp Dermatol. 2004;13(Suppl 4):16-21. doi:10.1111/j.1600-0625.2004.00256.x

18. Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin. 2014;32(3):369-384. doi:10.1016/j.det.2014.03.001